SV2017005527A - Agente terapéutico para disfunción del lóbulo frontal - Google Patents
Agente terapéutico para disfunción del lóbulo frontalInfo
- Publication number
- SV2017005527A SV2017005527A SV2017005527A SV2017005527A SV2017005527A SV 2017005527 A SV2017005527 A SV 2017005527A SV 2017005527 A SV2017005527 A SV 2017005527A SV 2017005527 A SV2017005527 A SV 2017005527A SV 2017005527 A SV2017005527 A SV 2017005527A
- Authority
- SV
- El Salvador
- Prior art keywords
- demorness
- demontime
- alteration
- lewy
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA UN AGENTE TERAPÉUTICO Y/O PREVENTIVO, POR EJEMPLO, PARA DISFUNCIÓN DEL LÓBULO FRONTAL (POR EJEMPLO, ALTERACIÓN COGNITIVA (POR EJEMPLO, ALTERACIÓN COGNITIVA EN ENFERMEDAD DE PARKINSON, ALTERACIÓN COGNITIVA CAUSADA POR ESTRÁS CRÓNICO, DEMENCIA CON CUERPOS DE LEWY, PARÁLISIS SUPRANUCLEAR PROGRESIVA, DEMENCIA FRONTOTEMPORAL, Y SIMILARES), Y OTROS), ENFERMEDAD DE CUERPOS DE LEWY (POR EJEMPLO, ALTERACIÓN COGNITIVA EN ENFERMEDAD DE PARKINSON, ENFERMEDAD DIFUSA DE CUERPOS DE LEWY, DEMENCIA CON CUERPOS DE LEWY, TRASTORNO DEL MOVIMIENTO ASOCIADO CON ENFERMEDAD DE CUERPOS DE LEWY, Y SIMILARES), Y OTROS, QUE CONTIENE UN COMPUESTO REPRESENTADO POR LA FÓRMULA (I) O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES COMO UN INGREDIENTE ACTIVO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015055532 | 2015-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SV2017005527A true SV2017005527A (es) | 2017-10-23 |
Family
ID=56919157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SV2017005527A SV2017005527A (es) | 2015-03-19 | 2017-08-29 | Agente terapéutico para disfunción del lóbulo frontal |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US20180042910A1 (es) |
| EP (1) | EP3270923B1 (es) |
| JP (1) | JP6869893B2 (es) |
| KR (1) | KR20170129764A (es) |
| CN (1) | CN107405341A (es) |
| AR (1) | AR103972A1 (es) |
| AU (1) | AU2016234211B2 (es) |
| BR (1) | BR112017018165A2 (es) |
| CA (1) | CA2978426A1 (es) |
| CL (1) | CL2017002351A1 (es) |
| CO (1) | CO2017008814A2 (es) |
| CR (1) | CR20170405A (es) |
| CY (1) | CY1124459T1 (es) |
| DK (1) | DK3270923T3 (es) |
| DO (1) | DOP2017000206A (es) |
| EA (1) | EA032511B1 (es) |
| EC (1) | ECSP17069712A (es) |
| ES (1) | ES2884846T3 (es) |
| GE (1) | GEP20197007B (es) |
| HK (1) | HK1249059A1 (es) |
| HR (1) | HRP20211340T1 (es) |
| HU (1) | HUE055387T2 (es) |
| IL (1) | IL254196A0 (es) |
| JO (1) | JO3544B1 (es) |
| LT (1) | LT3270923T (es) |
| MX (1) | MX2017012020A (es) |
| MY (1) | MY196076A (es) |
| PE (1) | PE20171621A1 (es) |
| PL (1) | PL3270923T3 (es) |
| PT (1) | PT3270923T (es) |
| RS (1) | RS62311B1 (es) |
| SG (1) | SG11201707012YA (es) |
| SI (1) | SI3270923T1 (es) |
| SV (1) | SV2017005527A (es) |
| TN (1) | TN2017000369A1 (es) |
| TW (1) | TWI723012B (es) |
| UA (1) | UA123578C2 (es) |
| WO (1) | WO2016148308A1 (es) |
| ZA (1) | ZA201706136B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113016719B (zh) * | 2019-12-24 | 2022-08-02 | 复旦大学附属华山医院 | 一种突触核蛋白病理性快动眼睡眠行为障碍模型的制备法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE325610T1 (de) | 1997-09-05 | 2006-06-15 | Kyowa Hakko Kogyo Kk | Xanthinderivative zur behandlung von hirnischämie |
| AU2004309279B2 (en) | 2003-12-26 | 2010-07-15 | Kyowa Kirin Co., Ltd. | Thiazole derivative |
| EP2210891A1 (en) * | 2009-01-26 | 2010-07-28 | Domain Therapeutics | New adenosine receptor ligands and uses thereof |
| TWI548411B (zh) * | 2009-04-28 | 2016-09-11 | Kyowa Hakko Kirin Co Ltd | Exercise disorder treatment |
| UA113383C2 (xx) * | 2009-09-02 | 2017-01-25 | Терапевтичний агент для лікування тривожних розладів | |
| UA110097C2 (uk) * | 2009-09-02 | 2015-11-25 | Терапевтичний агент для лікування розладів настрою | |
| WO2012060844A1 (en) | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
-
2016
- 2016-03-17 JO JOP/2016/0045A patent/JO3544B1/ar active
- 2016-03-18 AU AU2016234211A patent/AU2016234211B2/en not_active Ceased
- 2016-03-18 KR KR1020177026576A patent/KR20170129764A/ko not_active Application Discontinuation
- 2016-03-18 TW TW105108544A patent/TWI723012B/zh not_active IP Right Cessation
- 2016-03-18 GE GEAP201614604A patent/GEP20197007B/en unknown
- 2016-03-18 CA CA2978426A patent/CA2978426A1/en not_active Abandoned
- 2016-03-18 LT LTEP16765135.5T patent/LT3270923T/lt unknown
- 2016-03-18 AR ARP160100730A patent/AR103972A1/es unknown
- 2016-03-18 MY MYPI2017703320A patent/MY196076A/en unknown
- 2016-03-18 PE PE2017001525A patent/PE20171621A1/es unknown
- 2016-03-18 ES ES16765135T patent/ES2884846T3/es active Active
- 2016-03-18 JP JP2017547186A patent/JP6869893B2/ja active Active
- 2016-03-18 EP EP16765135.5A patent/EP3270923B1/en active Active
- 2016-03-18 DK DK16765135.5T patent/DK3270923T3/da active
- 2016-03-18 WO PCT/JP2016/059788 patent/WO2016148308A1/en active Application Filing
- 2016-03-18 HU HUE16765135A patent/HUE055387T2/hu unknown
- 2016-03-18 EA EA201792070A patent/EA032511B1/ru unknown
- 2016-03-18 CN CN201680012849.8A patent/CN107405341A/zh active Pending
- 2016-03-18 CR CR20170405A patent/CR20170405A/es unknown
- 2016-03-18 MX MX2017012020A patent/MX2017012020A/es unknown
- 2016-03-18 RS RS20211061A patent/RS62311B1/sr unknown
- 2016-03-18 TN TNP/2017/000369A patent/TN2017000369A1/en unknown
- 2016-03-18 SG SG11201707012YA patent/SG11201707012YA/en unknown
- 2016-03-18 PT PT167651355T patent/PT3270923T/pt unknown
- 2016-03-18 PL PL16765135T patent/PL3270923T3/pl unknown
- 2016-03-18 UA UAA201709985A patent/UA123578C2/uk unknown
- 2016-03-18 SI SI201631316T patent/SI3270923T1/sl unknown
- 2016-03-18 US US15/558,240 patent/US20180042910A1/en not_active Abandoned
- 2016-03-18 BR BR112017018165A patent/BR112017018165A2/pt not_active Application Discontinuation
-
2017
- 2017-08-29 IL IL254196A patent/IL254196A0/en unknown
- 2017-08-29 CO CONC2017/0008814A patent/CO2017008814A2/es unknown
- 2017-08-29 SV SV2017005527A patent/SV2017005527A/es unknown
- 2017-09-08 ZA ZA2017/06136A patent/ZA201706136B/en unknown
- 2017-09-11 DO DO2017000206A patent/DOP2017000206A/es unknown
- 2017-09-15 CL CL2017002351A patent/CL2017002351A1/es unknown
- 2017-10-18 EC ECIEPI201769712A patent/ECSP17069712A/es unknown
-
2018
- 2018-07-11 HK HK18108966.3A patent/HK1249059A1/zh unknown
-
2021
- 2021-08-20 HR HRP20211340TT patent/HRP20211340T1/hr unknown
- 2021-08-25 CY CY20211100762T patent/CY1124459T1/el unknown
- 2021-09-03 US US17/466,772 patent/US20210393606A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2016000286A (es) | Compuesto heterocíclico que contiene nitrógeno | |
| CR20160485A (es) | Compuesto de ciclopropanamina y sus usos | |
| CO2019013707A2 (es) | Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson | |
| BR112017009497A2 (pt) | polinucleotídeos de aadc para o tratamento da doença de parkinson | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| CL2019000625A1 (es) | Combinación de agonistas de fxr. | |
| CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
| DOP2016000290A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| DOP2016000289A (es) | Compuestos heteroaromáticos y su uso como ligandos de dopamina d1 | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| CL2017001407A1 (es) | Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson | |
| SV2017005527A (es) | Agente terapéutico para disfunción del lóbulo frontal | |
| CO2021007442A2 (es) | Compuesto de 1,3,4-oxadiazolona y fármaco | |
| CO2020001792A2 (es) | Combinaciones farmacéuticas | |
| BR112018072255A2 (pt) | azasteroides para tratamento de tuberculose | |
| UY35989A (es) | Uso de paricalcitol en el tratamiento de la anemia inflamatoria | |
| ECSP18006622A (es) | Derivados de 2,3-dihidro-4h-1,3-benzoxazin-4-ona como moduladores de receptor muscarinico m1 cholinergico | |
| BR112018077112A2 (pt) | uso de liso-gb1 como alvo capaz de ser modulado por um fármaco | |
| AR110957A1 (es) | Agente terapéutico oral para tiroides | |
| BR112016030599A8 (pt) | novos derivados de aminoalquilbenzotiazepina e suas utilizações | |
| BR112016024918A2 (pt) | ?uso de uma droga? |